Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ambrisentan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB known ✓ | P24530 | 16/20 | 1.00 |
| ▸ | EDNRA known ✓ | P25101 | 16/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | KCNE1 | P15382 | 1/20 | 1.00 |
| ▸ | KCNQ1 | P51787 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | IL36G | Q9NZH8 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ambrisentan SCHEMBL3679 | 1.00 | EDNRB (1.00) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| Ambrisentan SCHEMBL3023434 | 1.00 | EDNRB (1.00) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| Ambrisentan SCHEMBL20769813 | 1.00 | EDNRB (1.00) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL7934042 | 0.91 | EDNRB (1.00) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL2352546 | 0.90 | EDNRB (0.81) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL2356501 | 0.90 | EDNRB (0.81) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL3023829 | 0.89 | EDNRB (0.83) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL3023827 | 0.89 | EDNRB (0.83) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL3028683 | 0.89 | EDNRB (0.80) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL7933350 | 0.89 | EDNRB (1.00) | EDNRBEDNRANR1I2KCNE1KCNQ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2476670-A1 | Stable solid salts of ambrisentan | Zentiva, K.S. (CZ) | 2012-07-18 | — | — | EP | claimed |
| US-12551475-B2 | Methods and compositions for treating RNA viral infections | MODEL MEDICINES, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4667008-A2 | METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONS | Model Medicines, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-4608396-A1 | TREATMENT OF IGA NEPHROPATHY USING AN ENDOTHELIN RECEPTOR ANTAGONIST AND AN APRIL BINDING ANTIBODY | Chinook Therapeutics, Inc. (US) | 2025-09-03 | — | — | EP | disclosed |
| EP-4014968-B1 | A FILM COATED TABLET COMPRISING MICRONIZED AMBRISENTAN | SANOVEL ILAC SANAYI VE TICARET AS (TR) | 2025-01-29 | — | — | EP | disclosed |
| US-20250025454-A1 | USE OF PIPENDOXIFENE TO TREAT SARS-COV-2 INFECTION | MODEL MEDICINES INC (US) | 2025-01-23 | — | — | US | disclosed |
| WO-2024092240-A1 | TREATMENT OF IGA NEPHROPATHY USING AN ENDOTHELIN RECEPTOR ANTAGONIST AND AN APRIL BINDING ANTIBODY | CHINOOK THERAPEUTICS, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| US-20240082228-A1 | SARS-COV-2 THERAPEUTICS | MODEL MEDICINES INC (US) | 2024-03-14 | — | — | US | disclosed |
| EP-4281180-A1 | SARS-COV-2 THERAPEUTICS | Model Medicines, Inc. (US) | 2023-11-29 | — | — | EP | disclosed |
| US-20230346792-A1 | COMPOSITIONS AND METHODS FOR TREATING LUNG INFLAMMATION | HOTH THERAPEUTICS, INC. | 2023-11-02 | — | — | US | disclosed |
| WO-2011004402-A2 | IMPROVED PROCESS FOR THE PREPARATION OF AMBRISENTAN AND NOVEL INTERMEDIATES THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2011-01-13 | — | — | WO | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20100204163-A1 | METABOLITES AND DERIVATIVES OF AMBRISENTAN | GILEAD COLORADO, INC. (US) | 2010-08-12 | — | — | US | disclosed |
| EP-2183223-A2 | METABOLITES AND DERIVATIVES OF AMBRISENTAN | Gilead Colorado, Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| US-20090311266-A1 | Inhibitors of the endothelin signalling pathway and alphavbeta3 integrin receptor antagonists for combination therapy | BASF AKTIENGESELLSCHAFT (DE) | 2009-12-17 | — | — | US | disclosed |
| EP-2118073-A2 | SELECTIVE ENDOTHELIN TYPE-A ANTAGONISTS | Concert Pharmaceuticals Inc. (US) | 2009-11-18 | — | — | EP | disclosed |
| WO-2009127251-A1 | COMBINATIONS COMPRISING A RENIN INHIBITOR | NOVARTIS AG (CH) | 2009-10-22 | — | — | WO | disclosed |
| WO-2009017777-A2 | METABOLITES AND DERIVATIVES OF AMBRISENTAN | GILEAD COLORADO, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| US-20080262006-A1 | Selective endothelin type-a antagonists | CONCERT PHARMACEUTICALS, INC. | 2008-10-23 | — | — | US | disclosed |
| WO-2008097468-A2 | SELECTIVE ENDOTHELIN TYPE-A ANTAGONISTS | CONCERT PHARMACEUTICALS, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12551475-B2 | Methods and compositions for treating RNA viral infections | SARS1, EIF2AK2, SNRPE | EDNRB 2670/4885EDNRA 3022/4885NR1I2 558/4885 |
| US-20080262006-A1 | Selective endothelin type-a antagonists | EDNRA, EDNRB, ECE1 | EDNRB 2/4885EDNRA 1/4885NR1I2 649/4885 |
| US-20090311266-A1 | Inhibitors of the endothelin signalling pathway and alphavbeta3 integrin receptor antagonists for combination therapy | EDNRB, EDNRA, ITGB3 | EDNRB 1/4885EDNRA 2/4885NR1I2 1214/4885 |
| US-20250025454-A1 | USE OF PIPENDOXIFENE TO TREAT SARS-COV-2 INFECTION | EIF2AK2, ACE2, SARS1 | EDNRB 1136/4885EDNRA 1580/4885NR1I2 381/4885 |
| US-20100204163-A1 | METABOLITES AND DERIVATIVES OF AMBRISENTAN | EDNRA, UGT1A3, EDNRB | EDNRB 3/4885EDNRA 1/4885NR1I2 454/4885 |
| US-20230346792-A1 | COMPOSITIONS AND METHODS FOR TREATING LUNG INFLAMMATION | ACE2, TMPRSS2, VIPR1 | EDNRB 142/4885EDNRA 94/4885NR1I2 1714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.